Skip to main content

Finerenone: Current role in CKD and T2DM Management

Staff looking at poster

​BC Renal staff review posters

This session will provide a review of finerenone’s role in the treatment of CKD patients with type 2 diabetes (T2DM). Topics will include new updates on the treatment of CKD in T2DM, with a focus on the role of finerenone in this population.

  • Dr. Mark Elliott, Nephrologist & Clinical Assistant Professor, Division of Nephrology, Dept of Medicine, UBC

This session is part of the ongoing Kidney Care staff education sessions. BC Renal's kdney care committee sponsors education webinars for kidney care clinic staff. 

The sessions provide practical information on a range of topics, with the goal of keeping  staff up-to-date on new practices in kidney care. 

Sessions are moderated and interactive, with discussion and questions from participants encouraged. 

SOURCE: Finerenone: Current role in CKD and T2DM Management ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Renal. All Rights Reserved.

    Copyright © 2024 Provincial Health Services Authority